Related to CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand

• Medicago Wins $21M DARPA Award to Scale Up Production of Flu Vaccines
  
• NIH Bankrolls Six Centers with $100M to Characterize Human Immune Responses
  
• Lonza Acquires Vivante to Expand into Viral-Based GMP Manufacturing
  
• Pevion’s Investors Commit Further $9.7M to Progress Virosome-Based Vaccines
  
• Okairos Obtains €16M to Advance T-Cell Vaccines for Infectious Diseases
  
• J&J and Crucell in Advanced Negotiations for €1.75B Acquisition Deal
  
• GSK Obtains Rights to Delphi’s Antibiotic-Free Tech for Recombinant Vaccines
  
• MedImmune Nabs Rights to IDC’s GLA Adjuvant for Infectious Disease Vaccines
  
• Thermo Fisher Scientific Takes Over Lomb Scientific
  
• Takeda Snags Exclusive License to Baxter’s Vero Cell Culture Tech for Flu Vaccine
  
• Inviragen and Duke-NUS Form Vaccine Partnership to Tackle Emerging Infectious Diseases
  
• Soligenix Nabs Exclusive License to Vaccine Thermostabilization Technology
  
• Dutch Ministry Puts Public Vaccine Production Site up for Sale
  
• LGLS Licenses Novavax’ VLP Technology to Develop Flu Vaccines for South Korea and Other Emerging Markets
  
• Crucell to Use Pepscan’s CLIPS Technology for Development of Infectious Disease Vaccines
  
• Medicago Achieves $3.8M Milestone under DARPA Contract to Build Vaccine Plant
  
• Biovest and Ordway Research Institute to Evaluate Firm's Technology for Producing Virus-Fighting Products
  
• Northwest Biotherapeutics Signs on Fraunhofer IZI for Brain Cancer Vaccine Development
  
• Lab21 Takes Over Myconostica to Expand Portfolio of Diagnostics for Fungal Infections
  
• Transgene and Vivalis to Evaluate MVA Vaccine Production in EB66 Duck Stem Cell Line